Drugs / HTL0039732
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05944237 | Aug 2023 → Dec 2028 expected | castration-resistant prostate carcinoma, colorectal neoplasm, gastric neoplasm, head and neck neoplasm +9 | Cancer Research UK | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-10-21 | Nxera Pharma UK Limited | Results Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO nxera.life ↗
HTL0039732, was found to be well-tolerated, confirmed target engagement and demonstrated encouraging early efficacy in two distinct tumor types when administered in combination use with atezolizumab |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-21 | Nxera Pharma UK Limited | Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO nxera.life ↗ |
| 2025-09-17 | Nxera Pharma UK Limited | Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732 nxera.life ↗ |
| 2024-09-13 | Nxera Pharma UK Limited | Nxera’s Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO nxera.life ↗ |
| 2023-08-10 | Nxera Pharma UK Limited | Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase 1/2a Trial with Cancer Immunotherapy Drug HTL0039732 nxera.life ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HTL0039732 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05944237 ↗ |
| Known as | HTL | “HTL0039732 (HTL) is a novel E-type prostanoid receptor 4 (EP4) antagonist for the treatment of advanced solid tumors.” PMID 42558019 ↗ Aug 2026 |
| Action | Inhibit | “HTL0039732 is a small molecule drug that blocks activation of EP4 receptors by prostaglandin E2 (PGE2), a naturally occurring substance in the body.” NCT05944237 ↗ |
| Modality | Small molecule | “HTL0039732 is a small molecule drug” NCT05944237 ↗ |
| Route | Oral | “HTL0039732 Capsules will be administered orally to fasted participants” NCT05944237 ↗ |